Concepedia

Michael Constantine

MC

Statistics

Publications

13

Citations

941

H-Index

12

Active since

1998

Affiliations

Dana-Farber Cancer Institute(Current)

Massachusetts General Hospital

Harvard University

Beth Israel Deaconess Medical Center

St. Luke's Mountain States Tumor Institute

Michael Constantine is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and pharmacology.

Publications per year

1998–2024

13

Publications

13

HIGH DOSE BICALUTAMIDE FOR ANDROGEN INDEPENDENT PROSTATE CANCER: EFFECT OF PRIOR HORMONAL THERAPY

Robin Joyce, Mary Anne Fenton, Michael Constantine et al. · The Journal of Urology · 1998 · 206 citations

Medicine, Endocrinology, Oncology +10

Effect of High-Dose vs Standard-Dose Vitamin D<sub>3</sub> Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer

Kimmie Ng, Halla Nimeiri, Nadine J. McCleary et al. · JAMA · 2019 · 185 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer

Deborah Schrag, Hajime Uno, Rachel Rosovsky et al. · JAMA · 2023 · 141 citations · Full text

Medicine, Hematology, Pharmacotherapy +17

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

Sara M. Tolaney, Nabihah Tayob, Chau T. Dang et al. · Journal of Clinical Oncology · 2021 · 139 citations · Full text

Medicine, Oncology, Pharmacology +14

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma

Irene M. Ghobrial, Chia‐Jen Liu, Oksana Zavidij et al. · American Journal of Hematology · 2019 · 61 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

1–5 of 13